(Q28235398)

1

0 references

author name string

Susanna Santagni

2

0 references

Erika Rattighieri

3

0 references

Elisa Chierchia

4

0 references

Giulia Despini

5

0 references

Giulia Marini

6

0 references

Alessia Prati

Gynecological Endocrinology

7

0 references

language of work or name

English

0 references

publication date

June 2014

0 references

published in

0 references

volume

30

0 references

issue

6

0 references

page(s)

438-43

0 references

cites work

Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.3109/09513590.2014.897321

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

20 April 2017

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Use of metformin in the treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Estimation of instantaneous secretory rates and intrinsic characteristics of luteinizing hormone secretion in women with Kallmann syndrome before and after estriol administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Increased Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome Is Unaltered by Prolonged Insulin Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321

Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2014.897321